Clinical Trials
43 trialsNCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT00135200 2025-04-30
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00006695 2023-09-01
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT01484093 2023-08-16
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00479167 2021-11-04
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Rush University Medical Center
Phase 2 Terminated
NCT00329030 2021-11-01
BMTCTN0401
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00992992 2019-12-04
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
GlaxoSmithKline
Phase 2 Completed
NCT00770224 2019-08-28
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00777114 2018-08-13
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Weill Medical College of Cornell University
Phase 1 Completed
NCT00004874 2018-01-17
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Terminated
NCT00476047 2017-10-12
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01536561 2017-08-31
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 1 Completed
NCT00073918 2017-08-18
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00992758 2017-07-25
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement
GlaxoSmithKline
Phase 1 Completed
NCT00577629 2017-05-30
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Duke University
Phase 2 Completed
NCT00490009 2017-03-30
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Stanford University
Phase 2 Completed
NCT00490490 2017-03-29
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
Stanford University
Phase 2 Terminated
NCT01389076 2017-01-30
Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00933335 2017-01-18
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
GlaxoSmithKline
Phase 2 Completed
NCT00950755 2017-01-18
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
GlaxoSmithKline
Phase 2 Completed
NCT00996996 2017-01-11
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 2 Completed
NCT01663714 2017-01-11
Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.
GlaxoSmithKline
Phase 2 Completed
NCT00268983 2017-01-09
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
GlaxoSmithKline
Phase 3 Completed
NCT00938041 2017-01-09
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
GlaxoSmithKline
Phase 2 Completed
NCT01868035 2017-01-09
Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP
GlaxoSmithKline
Phase 2 Completed
NCT00989664 2016-12-13
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 2 Completed
NCT01224821 2016-12-12
RIT-II-001
GlaxoSmithKline
Phase 2 Completed
NCT00996593 2016-11-23
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
GlaxoSmithKline
Phase 2 Completed
NCT00434629 2016-08-17
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
University of Pennsylvania
Phase 1 Completed
NCT00107380 2016-03-07
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00319332 2015-04-17
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
GlaxoSmithKline
Phase 3 Withdrawn
NCT00073931 2015-02-05
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00110071 2014-08-06
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00003784 2013-01-24
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00240565 2012-08-13
Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 2 Completed
NCT00475332 2012-02-15
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
University of Florida
Phase 2 Terminated
NCT00062894 2007-09-17
Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
GlaxoSmithKline
Phase 1/2 Completed
NCT00022880 2005-06-24
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia
Corixa Corporation
Phase 1 Unknown
NCT00022893 2005-06-24
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
Corixa Corporation
Phase NA Unknown
NCT00022906 2005-06-24
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement
Corixa Corporation
Phase 1 Unknown
NCT00022932 2005-06-24
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
Corixa Corporation
Phase 2 Unknown
NCT00022945 2005-06-24
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Corixa Corporation
Phase 2 Completed
NCT00022958 2005-06-24
Expanded Access Study of Iodine-131 Anti-B1 Antibody
Corixa Corporation
Phase NA Unknown